Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2017 Sep 26;12(9):e0185398.
doi: 10.1371/journal.pone.0185398. eCollection 2017.

Validation of participant eligibility for pre-exposure prophylaxis: Baseline data from the PRELUDE demonstration project

Stefanie J Vaccher  1 , Andrew E Grulich  1 , Bridget G Haire  1 , Damian P Conway  1   2 , Isobel M Poynten  1 , Catriona Ooi  3 , Rosalind Foster  1   4 , David J Templeton  1   5 , Iryna B Zablotska  1 ; PRELUDE Study Team
Affiliations
Observational Study

Validation of participant eligibility for pre-exposure prophylaxis: Baseline data from the PRELUDE demonstration project

Stefanie J Vaccher et al. PLoS One. .

Abstract

Background: In Australia, pre-exposure prophylaxis (PrEP) is targeted to individuals at high risk for HIV infection. We describe the HIV risk profile and characteristics of PRELUDE participants, and evaluate the population validity of the sample in representing high-risk gay and bisexual men (GBM) eligible for PrEP.

Methods: PRELUDE is an on-going, open-label, single-arm observational study. Participants were identified in clinics and screened for eligibility using a paper-based risk assessment tool which followed the New South Wales (NSW) PrEP guidelines. Selection was validated using an independent online behavioural survey, completed by study participants upon enrolment. Demographic information was analysed using descriptive statistics, and kappa tests were used to determine agreement between reporting of high-risk practices in the risk assessment and behavioural survey.

Results: During 2014-15, 471 individuals were targeted for enrolment; 341 were assessed for PrEP eligibility and 313 were enrolled. Of these, 303 (97%) identified as GBM. Overall, 85% of GBM met at least one high-risk criterion; 68% reported receptive intercourse with an HIV-positive or unknown status casual male partner, and 37% reported methamphetamine use in the three months preceding enrolment. The remaining 15% were enrolled based on medium-risk behaviours, or at the clinicians' discretion. We found an 82% total agreement between self-reported high-risk behaviour and clinicians' categorisation of GBM as being at high risk for HIV based on PrEP eligibility criteria.

Conclusions: Behavioural eligibility criteria used by clinicians successfully identified individuals at high risk for HIV infection. This targeted approach ensures that the greatest public health and HIV prevention benefits can be derived in a setting without universal access to PrEP.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: AG has research funding from Seqirus, Gilead, Viiv, and in-kind research support from Hologic. He has received travel funding from Gilead. IZ has received research funding and in-kind support (supply of the study medication) from Gilead Sciences Inc. The remaining authors have declared that no competing interests exist. This does not alter our adherence to PLOS ONE policies on sharing data and materials. The minimal data set used in this manuscript is available in a stable public repository for any interested party.

Figures

Fig 1
Fig 1. CONSORT flow diagram.
Fig 2
Fig 2. New South Wales HIV pre-exposure prophylaxis behavioural eligibility criteria for gay and bisexual men.
Fig 3
Fig 3. Comparison of high-risk behaviours reported in the paper-based risk assessment and online behavioural survey (n = 305).
HR1: Had an HIV-positive regular partner with whom condoms were not consistently used; HR2: Had receptive intercourse with a casual male partner of HIV-positive or unknown status; HR3: Been diagnosed rectal chlamydia or gonorrhoea; HR4: Methamphetamine use.
See this image and copyright information in PMC

References

    1. Fonner VA, Dalglish SL, Kennedy CE, Baggaley R, O'Reilly KR, Koechlin FM, et al. Effectiveness and safety of oral HIV preexposure prophylaxis for all populations. AIDS. 2016;30(12): 1973–83. doi: 10.1097/QAD.0000000000001145 - DOI - PMC - PubMed
    1. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27): 2587–99. doi: 10.1056/NEJMoa1011205 - DOI - PMC - PubMed
    1. Molina JM, Capitant C, Spire B, Pialoux G, Cotte L, Charreau I, et al. On-demand preexposure prophylaxis in men at high risk for HIV-1 infection. N Engl J Med. 2015;373(23): 2237–46. doi: 10.1056/NEJMoa1506273 - DOI - PubMed
    1. McCormack S, Dunn DT, Desai M, Dolling DI, Gafos M, Gilson R, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet. 2015;387(10013): 53–60. doi: 10.1016/S0140-6736(15)00056-2 - DOI - PMC - PubMed
    1. Baeten JM, Heffron R, Kidoguchi L, Mugo N, Katabira E, Bukusi E, et al. Integrated delivery of PrEP and ART results in sustained near elimination of HIV transmission in African HIV serodiscordant couples: final results from The Partners Demonstration Project. AIDS2016; 2016. Durban (South Africa).

Publication types